Management of ‘OFF’ Episodes in Parkinson’s Disease | NDT – Dove Medical Press

Related Articles:

• The road ahead: 2022 January 20, 2022 # # # # The first post at the start of each year on the SoPD website tries to provide an overview of where things are in the search for ‘disease modifying’ therapies for Parkinson’s.  It is an exercise in managing expectations as well as discussing what research events are scheduled for the next year so that we can keep…
• Real-world assessment of "OFF" episode-related healthcare resource utilization among patients with Parkinson's disease in the United States April 5, 2021 J Med Econ. 2021 Apr 5:1. doi: 10.1080/13696998.2021.1913009. Online ahead of print.ABSTRACTAIMS: Within 5 years of initiating carbidopa/levodopa, ∼50% of patients with Parkinson's disease (PD) experience "OFF" episodes; little is known about the cost burden. We investigated the association of "OFF" episodes with patient characteristics, healthcare resource utilization (HCRU), and healthcare costs.METHODS: Analyses used neurologist-provided data from the US-specific 2017…
• Real-world assessment of "OFF" episode-related healthcare resource utilization among patients with Parkinson's disease in the United States April 5, 2021 J Med Econ. 2021 Apr 5:1. doi: 10.1080/13696998.2021.1913009. Online ahead of print.ABSTRACTAIMS: Within 5 years of initiating carbidopa/levodopa, ∼50% of patients with Parkinson's disease (PD) experience "OFF" episodes; little is known about the cost burden. We investigated the association of "OFF" episodes with patient characteristics, healthcare resource utilization (HCRU), and healthcare costs.METHODS: Analyses used neurologist-provided data from the US-specific 2017…
• Real-world assessment of "OFF" episode-related healthcare resource utilization among patients with Parkinson's disease in the United States April 5, 2021 J Med Econ. 2021 Apr 5:1. doi: 10.1080/13696998.2021.1913009. Online ahead of print.ABSTRACTAIMS: Within 5 years of initiating carbidopa/levodopa, ∼50% of patients with Parkinson's disease (PD) experience "OFF" episodes; little is known about the cost burden. We investigated the association of "OFF" episodes with patient characteristics, healthcare resource utilization (HCRU), and healthcare costs.METHODS: Analyses used neurologist-provided data from the US-specific 2017…
• Real-world assessment of "OFF" episode-related healthcare resource utilization among patients with Parkinson's disease in the United States April 5, 2021 J Med Econ. 2021 Apr 5:1. doi: 10.1080/13696998.2021.1913009. Online ahead of print.ABSTRACTAIMS: Within 5 years of initiating carbidopa/levodopa, ∼50% of patients with Parkinson's disease (PD) experience "OFF" episodes; little is known about the cost burden. We investigated the association of "OFF" episodes with patient characteristics, healthcare resource utilization (HCRU), and healthcare costs.METHODS: Analyses used neurologist-provided data from the US-specific 2017…
• The road ahead: 2021 January 25, 2021 # # # # At the start of each year, it is a useful practise to layout what is planned over the next 12 months. The events that are scheduled for the year to come, so that we can keep an eye out for them. Obviously, where 2021 will end actually is unpredictable, but an outline of what is scheduled…
• Monthly Research Review: January 2022 January 31, 2022 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during January 2022. The post is divided into 10 parts based on the type of research: Top 6 pieces of Parkinson’s news Articles of general interest Basic biology…
• Monthly Research Review – September 2021 September 30, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during September 2021. The post is divided into 10 parts based on the type of research: Top 4 pieces of Parkinson’s news Articles of general interest Basic biology…
• FDA Approves Kynmobi Sublingual Film to Treat Off Episodes in Parkinson’s May 22, 2020 The U.S. Food and Drug Administration has approved Sunovion’s Kynmobi (apomorphine hydrochloride) as an on-demand sublingual treatment for off episodes, or times when medication wears off, in people with Parkinson’s disease. The medication, formerly known as APL-130277, is an apomorphine film that is placed under-the-tongue (sublingual administration) when patients start experiencing a worsening of their symptoms. It can be taken up to five…
• The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
• Depression in parkinson's disease at high altitude - NDT | NDT - Dove Medical Press May 5, 2021 Depression in parkinson's disease at high altitude - NDT | NDT  Dove Medical Press
• Monthly research review – March 2021 March 31, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during March 2021. The post is divided into ten parts based on the type of research: Top 5 pieces of Parkinson’s news Articles of general interest Basic biology…
• 2020: Year in Review January 1, 2021 # # # # In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2020. Month-by-month we will briefly discuss some of the major pieces of research/ announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies…
• FDA Accepts Resubmitted New Drug Application for APL-130277 Apomorphine Film, Sunovion Announces January 6, 2020 The U.S. Food and Drug Administration has accepted Sunovion‘s resubmitted new drug application (NDA) for APL-130277, an oral apomorphine therapy for treating off episodes in Parkinson’s disease. The FDA had asked for additional information regarding APL-130277, following the first NDA in mid-2018. A response to this resubmission is expected by May 21. APL-130277 is an under-the-tongue (sublingual) apomorphine film that…
• Monthly Research Review – February 2021 February 28, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during February 2021. The post is divided into eight parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news…
• Current Perspectives on the Assessment and Management of Gait Disorder | NDT - Dove Medical Press September 21, 2021 Current Perspectives on the Assessment and Management of Gait Disorder | NDT  Dove Medical Press
• Correlation between Lacunae & Wearing-off Phenomenon in PD | NDT - Dove Medical Press January 10, 2022 Correlation between Lacunae & Wearing-off Phenomenon in PD | NDT  Dove Medical Press
• Monthly research review – April 2021 April 30, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during April 2021. The post is divided into 10 parts based on the type of research: Top 5 pieces of Parkinson’s news Articles of general interest Basic biology…
• Long-term Gocovri Lessens Parkinson’s Motor Symptoms for at Least 2 Years, Final Phase 3 Data Show February 20, 2020 Long-term treatment with Gocovri (amantadine) extended-release capsules was safe and led to sustained reductions in dyskinesia — involuntary, jerky movements — and off episodes in people with Parkinson’s disease, final data from a two-year Phase 3 clinical trial show. “As the longest-running amantadine study to date, this open-label trial suggests Gocovri may provide sustained improvement in both dyskinesia and OFF…
• Long-term Gocovri Lessens Parkinson’s Motor Symptoms for at Least 2 Years, Final Phase 3 Data Show February 20, 2020 Long-term treatment with Gocovri (amantadine) extended-release capsules was safe and led to sustained reductions in dyskinesia — involuntary, jerky movements — and off episodes in people with Parkinson’s disease, final data from a two-year Phase 3 clinical trial show. “As the longest-running amantadine study to date, this open-label trial suggests Gocovri may provide sustained improvement in both dyskinesia and OFF…
• Long-term Gocovri Lessens Parkinson’s Motor Symptoms for at Least 2 Years, Final Phase 3 Data Show February 20, 2020 Long-term treatment with Gocovri (amantadine) extended-release capsules was safe and led to sustained reductions in dyskinesia — involuntary, jerky movements — and off episodes in people with Parkinson’s disease, final data from a two-year Phase 3 clinical trial show. “As the longest-running amantadine study to date, this open-label trial suggests Gocovri may provide sustained improvement in both dyskinesia and OFF…
• Parkinson's Disease-Associated Melanin Steal [Retraction] | NDT - Dove Medical Press March 2, 2021 Parkinson's Disease-Associated Melanin Steal [Retraction] | NDT  Dove Medical Press